2026 Annual Meeting | Industry Therapeutic Update from Sanofi Medical: Ahead of the Curve: How Early Detection of Disability May Impact the MS Disease Course - Integrating Patient Perspectives, Clinical Insights, and Scientific Advances

Date Monday 04/20/26

Time 11:45 AM - 12:45 PM CDT Add To Calendar

Location McCormick Place West | W475

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) Multiple Sclerosis

Learning Objectives
Overall Objective: To explore the potential for more effective, early interventions into the progression of MS through the patient’s experience with input from a clinician and scientist.

To understand the role of the immune network in neuroinflammation in the CNS and the periphery, how neuroinflammation drives disability accumulation across the continuum of MS, and how disrupting different parts of this continuum could restore homeostasis in CNS microenvironments and prevent/halt disability progression (Scientist presents data; Patient shares a personal anecdote about disability accumulation)
To recognize the early signs of disability in MS in the clinic, why clinically stable patients might be progressing (Scientist presents data; Clinician presents how to detect PIRA; Patient shares lived experience)
To understand emerging tools used to detect MS early in the clinic and the patient perspectives on current and future detection and monitoring strategies

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
11:45 AM - 12:45 PM CDT	Speaker	Industry Therapeutic Update from Sanofi Medical: Ahead of the Curve: How Early Detection of Disability May Impact the MS Disease Course - Integrating Patient Perspectives, Clinical Insights, and Scientific Advances

Faculty Disclosures
Anita Williams, MSc	No disclosure on file
Scott D. Newsome, DO, F�鶹��ýӳ��	Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Newsome has received research support from Biogen. The institution of Dr. Newsome has received research support from Genentech/Roche. The institution of Dr. Newsome has received research support from Department of Defense. The institution of Dr. Newsome has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Newsome has received research support from National MS Society. The institution of Dr. Newsome has received research support from Lundbeck. The institution of Dr. Newsome has received research support from Sanofi. The institution of Dr. Newsome has received research support from Kyverna Therapeutics. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving as a Lead PI for Clinical Trial with Roche.
Ahmed Abdelhak, MD	The institution of Dr. Abdelhak has received research support from German Multiple Sclerosis Society.

�鶹��ýӳ��

�鶹��ýӳ��